[(3S,8S,9S,10R,13R,14S,17R)-10,13-二甲基-17-[(2R)-6-甲基庚烷-2-基]-2,3,4,7,8,9,11,12,14,15,16,17-十二氢-1H-环戊二烯并[a]菲-3-基]N-(2-二甲基氨基乙基)氨基甲酸酯 | 137056-72-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: [(3S,8S,9S,10R,13R,14S,17R)-10,13-二甲基-17-[(2R)-6-甲基庚烷-2-基]-2,3,4,7,8,9,11,12,14,15,16,17-十二氢-1H-环戊二烯并[a]菲-3-基]N-(2-二甲基氨基乙基)氨基甲酸酯
• 英文名称: DC-cholesterol
• 英文别名: 3β-[N-(N',N'-dimethylaminoethyl)carbamoyl]cholesterol；DC-Chol；[(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] N-[2-(dimethylamino)ethyl]carbamate
• CAS: 137056-72-5
• 化学式: C₃₂H₅₆N₂O₂
• 分子量: 500.809
• InChiKey: HIHOWBSBBDRPDW-PTHRTHQKSA-N

物化性质

• 熔点：
  107.5-108.5 °C(Solv: ethanol (64-17-5))
• 沸点：
  578.1±39.0 °C(Predicted)
• 密度：
  1.01±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  9
• 重原子数：
  36
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• WGK Germany：
  3

反应信息

• 作为反应物：
  描述：

  [(3S,8S,9S,10R,13R,14S,17R)-10,13-二甲基-17-[(2R)-6-甲基庚烷-2-基]-2,3,4,7,8,9,11,12,14,15,16,17-十二氢-1H-环戊二烯并[a]菲-3-基]N-(2-二甲基氨基乙基)氨基甲酸酯 、 碘甲烷 以 二氯甲烷 为溶剂， 反应 4.0h， 以78%的产率得到2-(cholest-5-en-3β-yloxycarbonylamino)ethyltrimethylammonium iodide
  参考文献：
  名称：

  Synthesis of Cationic Cholesterol Derivatives with Fragments of Aliphatic Nitrogen-Containing Bases

  摘要：

  Cationic cholesterol derivatives were synthesized, in which fragments of aliphatic amines (2-dimethylaminoethanol, N,N-dimethylethylenediamine, and N,N,N',N'-tetramethylethylenediamine) are attached to the cholesterol backbone either directly or through a spacer ester or carbamate moiety. The products may be used as efficient agents for liposome-mediated transfection.

  DOI：

  10.1023/b:rujo.0000034966.03875.de
• 作为产物：
  描述：

  胆固醇 、 alkaline earth salt of/the/ methylsulfuric acid 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 21.0h， 生成 [(3S,8S,9S,10R,13R,14S,17R)-10,13-二甲基-17-[(2R)-6-甲基庚烷-2-基]-2,3,4,7,8,9,11,12,14,15,16,17-十二氢-1H-环戊二烯并[a]菲-3-基]N-(2-二甲基氨基乙基)氨基甲酸酯
  参考文献：
  名称：

  Synthesis of Cationic Cholesterol Derivatives with Fragments of Aliphatic Nitrogen-Containing Bases

  摘要：

  Cationic cholesterol derivatives were synthesized, in which fragments of aliphatic amines (2-dimethylaminoethanol, N,N-dimethylethylenediamine, and N,N,N',N'-tetramethylethylenediamine) are attached to the cholesterol backbone either directly or through a spacer ester or carbamate moiety. The products may be used as efficient agents for liposome-mediated transfection.

  DOI：

  10.1023/b:rujo.0000034966.03875.de
• 作为试剂：
  描述：

  C28H45ClO2 、 N,N-二甲基乙二胺 、 碘 在 Dricold ethanol 、 amine 、 [(3S,8S,9S,10R,13R,14S,17R)-10,13-二甲基-17-[(2R)-6-甲基庚烷-2-基]-2,3,4,7,8,9,11,12,14,15,16,17-十二氢-1H-环戊二烯并[a]菲-3-基]N-(2-二甲基氨基乙基)氨基甲酸酯 、 乙醇 、 氯仿 、 甲醇 作用下， 以 氯仿 为溶剂， 生成 [(3S,8S,9S,10R,13R,14S,17R)-10,13-二甲基-17-[(2R)-6-甲基庚烷-2-基]-2,3,4,7,8,9,11,12,14,15,16,17-十二氢-1H-环戊二烯并[a]菲-3-基]N-(2-二甲基氨基乙基)氨基甲酸酯
  参考文献：
  名称：

  Cationic amphiphiles

  摘要：

  本发明公开了一种用于细胞转染DNA的阳离子脂质。

  公开号：

  US06509032B1

文献信息

• PROCESS FOR PREPARING DC-CHOLESTEROL
  申请人：Palle Raghavendracharyulu Venkata

  公开号：US20070238889A1

  公开（公告）日：2007-10-11

  Processes for preparing 3β-[N-(N′,N′-dimethylaminoethane)-carbamoyl]cholesterol (“DC-cholesterol”) and its salts.

  制备3β-[N-(N′,N′-二甲基氨基乙基)-氨甲酰基]胆固醇（“DC-胆固醇”）及其盐的过程。
• Methods and compositions for determining the tumor suppressor status of
  申请人：Onyx Pharmaceuticals, Inc.

  公开号：US05876711A1

  公开（公告）日：1999-03-02

  Methods and compositions for determining the tumor suppressor status of cells are described, preferably as pertaining to the p53 status of tumor cells, and preferably in vivo using a recombinant construct consisting of a first polynucleotide sequence that encodes a reporter molecule and a second p53 binding polynucleotide sequence that is operably linked to the first polynucleotide sequence such that binding of p53 to the second polynucleotide sequence causes the expression of the reporter molecule which can be detected or quantified.

  本文描述了用于确定细胞肿瘤抑制剂状态的方法和组合物，最好是与肿瘤细胞的p53状态有关，并且最好在体内使用重组构建物。该构建物由第一聚核苷酸序列和编码报告分子的第二个p53结合聚核苷酸序列组成，两者之间可操作地链接，使得p53与第二聚核苷酸序列结合会导致报告分子的表达，从而可以检测或定量化。
• Liposomal-viral DNA complexes for treating disease
  申请人：Onyx Pharmaceuticals, Inc.

  公开号：US06133243A1

  公开（公告）日：2000-10-17

  Methods and compositions for treating cancer consisting of viral DNA in association with liposomal material, the viral DNA substantially incapable of encoding a functional viral oncoprotein capable of binding to a functional tumor suppressor gene product in a neoplastic cell, and the viral DNA capable of replicating and forming infectious virus in neoplastic cells thereby killing the neoplastic cells and substantially incapable of replicating and forming infectious virus in non-neoplastic cells that have the tumor suppressor protein.

  治疗癌症的方法和组合物，由与脂质体材料相关联的病毒DNA组成，该病毒DNA基本上无法编码具有结合功能的病毒致癌蛋白质的功能性肿瘤抑制基因产物的能力，在肿瘤细胞中能够复制并形成感染性病毒，从而杀死肿瘤细胞，并基本上无法在具有肿瘤抑制蛋白质的非肿瘤细胞中复制和形成感染性病毒。
• Methods for the suppression of neu mediated tumors by adenoviral E1A and
  申请人：Board of Regents, The University of Texas System

  公开号：US05641484A1

  公开（公告）日：1997-06-24

  Disclosed are methods and compositions for the suppression of expression of the neu oncogene, as well as suppression of neu oncogene-mediated transformation, tumorigenesis and metastasis. The method disclosed involves introduction of adenovirus early 1A gene (the E1A gene) products, so to large T antigen (the LT gene product), or both into affected cells. These products, which are preferably introduced by transfection of the E1A gene into affected cells, serve to suppress neu gene expression as measured by a reduction of p185 expression. Furthermore, the E1A gene products surprisingly serve to suppress the oncogenic phenotype, as indicated by a reduction in cell growth, growth in soft agar, as well as tumorigenic and metastatic potential in vivo. The inventors propose that E1A gene products, LT gene products or derivatives therefrom, may ultimately be employed a treatment modalities for neu-mediated cancers, such as cancers of the female genital tract and breast. The inventors also propose methods of transfecting cells with either the E1A or the LT gene products using liposomes.

  本发明涉及抑制neu癌基因表达的方法和组合物，以及抑制neu癌基因介导的转化、肿瘤发生和转移的方法。所述方法涉及将腺病毒早期1A基因（E1A基因）产物、大T抗原（LT基因产物）或两者同时引入受影响的细胞。这些产物，最好是通过转染E1A基因到受影响的细胞中引入，有助于通过降低p185表达来抑制neu基因表达。此外，E1A基因产物令人惊讶地能够抑制致癌表型，表现为细胞生长、软琼脂生长、以及在体内的肿瘤形成和转移潜力的降低。发明人认为，E1A基因产物、LT基因产物或其衍生物最终可能被用作neu介导的癌症的治疗方法，例如女性生殖道和乳腺癌。发明人还提出了使用脂质体将E1A或LT基因产物转染到细胞中的方法。
• Sensitization of HER-2/neu overexpressing cancer cells to chemotherapy
  申请人：Board of Regents, The University of Texas System

  公开号：US06395712B1

  公开（公告）日：2002-05-28

  The present invention relates to methods for the inhibition, of the gene product of the neu oncogene, p185neu tyrosine kinase. Over-expression of the neu oncogene leads to chemoresistance. The methods disclosed involve the novel use of E1A and/or LT in combination with chemotherapeutic drugs to treat carcinoma. Furthermore, E1A surprisingly potentiates the antineoplastic effects of the chemotherapeutic agents. The inventors propose that E1A sensitizes cancer cells such that they become amenable to treatment by chemotherapeutic drugs.

  本发明涉及抑制神经母细胞瘤癌基因产物p185neu酪氨酸激酶的方法。神经母细胞瘤癌基因的过度表达会导致化疗耐药。所披露的方法涉及使用E1A和/或LT与化疗药物结合治疗癌症。此外，E1A出人意料地增强了化疗药物的抗肿瘤效果。发明人认为，E1A使癌细胞变得敏感，从而可接受化疗药物的治疗。